Top Page
Ascletis Pharma, Inc.
(1672)
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Ascletis Pharma, Inc. Business Overview & Revenue Model
Ascletis Pharma, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.36M | 1.28M | 56.60M | 54.09M | 76.88M | 35.00M |
| Gross Profit | 856.00K | 735.00K | 25.99M | -24.69M | 39.17M | -23.50M |
| EBITDA | -408.21M | -390.45M | -126.09M | -284.50M | -169.35M | -181.94M |
| Net Income | -258.57M | -300.94M | -144.72M | -314.84M | -199.02M | -209.24M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.12B | 2.49B | 2.66B | 2.83B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.95B | 2.30B | 2.48B | 2.50B | 2.71B |
| Total Debt | 4.27M | 7.63M | 8.42M | 4.24M | 2.75M | 1.59M |
| Total Liabilities | 129.00M | 158.41M | 148.94M | 117.16M | 100.89M | 85.42M |
| Stockholders Equity | 1.87B | 1.97B | 2.34B | 2.54B | 2.73B | 2.98B |
Cash Flow | ||||||
| Free Cash Flow | -313.25M | -343.73M | -163.32M | -156.85M | -154.13M | -123.87M |
| Operating Cash Flow | -311.15M | -341.58M | -144.16M | -142.45M | -146.93M | -84.91M |
| Investing Cash Flow | 1.62B | 978.91M | 149.84M | -1.30B | -274.49M | 132.30M |
| Financing Cash Flow | -72.54M | -103.51M | -81.50M | -1.42M | -31.10M | -21.67M |
Ascletis Pharma, Inc. Technical Analysis
Ascletis Pharma, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$32.53B | 37.04 | 27.37% | ― | 2.57% | 18.79% | |
54 Neutral | HK$12.95B | -46.07 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$8.60B | -14.62 | -42.46% | ― | 1219.19% | 25.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$9.81B | -47.25 | -21.42% | ― | 240.05% | -140.09% | |
39 Underperform | HK$2.63B | -3.72 | -129.05% | ― | ― | -18.99% |
Ascletis Pharma, Inc. Corporate Events
Ascletis Pharma Inc. has announced the selection of its first oral GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, for clinical development. This drug candidate, developed using Ascletis’ proprietary technologies, has shown significantly higher bioavailability and potency compared to existing formulations in non-human primate studies. The company plans to submit an Investigational New Drug Application to the U.S. FDA in 2026, marking a significant step in addressing unmet needs in obesity treatment and strengthening Ascletis’ position in the pharmaceutical industry.
Ascletis Pharma Inc. has announced the co-formulation of ASC36, an amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist, both designed for once-monthly subcutaneous administration. The co-formulation demonstrated significant body weight reduction in preclinical studies and showed excellent stability, supporting its potential as a treatment for obesity. Ascletis plans to submit an Investigational New Drug Application to the FDA by the second quarter of 2026, marking a significant step in its clinical development pipeline.
Ascletis Pharma Inc. announced promising results from its Phase Ib studies of ASC30, both as an oral tablet and a subcutaneous injection, along with a preclinical study of a combination therapy involving ASC31 and ASC47. The oral tablet showed up to a 6.5% placebo-adjusted mean body weight reduction, with mild-to-moderate gastrointestinal adverse events, while the injection demonstrated an extended half-life supporting monthly and quarterly dosing schedules. These findings highlight the efficacy and safety of Ascletis’ obesity treatments and reinforce the company’s competitive positioning in the obesity drug market.
Ascletis Pharma Inc. has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, for clinical development targeting obesity. The preclinical studies indicate that ASC36 offers a significantly longer half-life and greater weight reduction compared to existing treatments, positioning it as a potentially best-in-class therapy. The company plans to submit an Investigational New Drug Application to the FDA by the second quarter of 2026, which could enhance its market positioning in the obesity treatment sector.
Ascletis Pharma Inc. announced it will present study results of its obesity treatment assets, including ASC30, ASC31, and ASC47, at ObesityWeek 2025 in Atlanta. These presentations highlight the company’s commitment to developing differentiated obesity treatments, with ASC30 being a new chemical entity with patent protection until 2044, and ASC31 and ASC47 showing promising results in preclinical studies.
Ascletis Pharma Inc. has completed enrollment for a U.S. Phase IIa study of its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30, aimed at treating obesity. This milestone marks significant progress in the development of ASC30, which has demonstrated a 46-day half-life, supporting its potential as a once-monthly treatment option. Topline data from this study are expected in the first quarter of 2026, potentially impacting the company’s market positioning in obesity treatment.
Ascletis Pharma Inc. has completed a pre-New Drug Application consultation with the China National Medical Products Administration for its drug denifanstat (ASC40), aimed at treating moderate-to-severe acne vulgaris. The drug has shown significant efficacy and a favorable safety profile in Phase III trials, with no severe adverse events reported. Ascletis plans to submit an NDA soon, which could enhance its market position in dermatological treatments in Greater China.
Ascletis Pharma Inc. has announced the selection of ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, for clinical development. ASC35 has shown promising results in preclinical studies, demonstrating a longer half-life and greater efficacy in weight reduction compared to tirzepatide, positioning it as a potentially best-in-class treatment for obesity. The company plans to submit an Investigational New Drug Application for ASC35 to the FDA by the second quarter of 2026, which could significantly impact its market positioning and offer scalability advantages in manufacturing.
Ascletis Pharma Inc. has announced its intention to repurchase up to 96,284,628 shares, equivalent to 10% of its issued shares, under a repurchase mandate approved by shareholders. The company plans to use up to HK$300 million of its internal financial resources for this initiative, aiming to enhance shareholder value and reflect confidence in its long-term business prospects. The repurchase will be conducted in compliance with relevant regulations and will not adversely impact the company’s financial position.
Ascletis Pharma Inc. has announced the grant of 650,000 share options to 10 employee participants under its 2025 Share Option Scheme. This move is part of the company’s strategy to incentivize its workforce, with options exercisable over a period of five years starting from 2026. The grant aims to align employee interests with company performance, although no specific performance targets are required for the options to vest. The announcement reflects Ascletis Pharma’s commitment to employee engagement and retention, potentially strengthening its position in the competitive pharmaceutical industry.
Ascletis Pharma Inc. announced that its weight loss drug candidate, ASC47, in combination with semaglutide, showed a significant reduction in body weight in obese participants compared to semaglutide alone. The study demonstrated better gastrointestinal tolerability and a lower rebound effect after treatment discontinuation, suggesting ASC47’s potential as a maintenance therapy. These findings could enhance Ascletis’s positioning in the weight management sector, offering a promising option for obesity treatment.
Ascletis Pharma Inc. announced the successful results of its Phase III clinical trial for Denifanstat (ASC40), a first-in-class FASN inhibitor for the treatment of moderate to severe acne vulgaris. The trial met all primary and secondary efficacy endpoints, demonstrating significant improvements in acne symptoms compared to placebo, with a favorable safety profile. The company is in the process of consulting with the China National Medical Products Administration (NMPA) for a New Drug Application (NDA), which could enhance its market positioning in dermatology and potentially benefit stakeholders by expanding its product portfolio.
Ascletis Pharma Inc. announced promising results from its Phase Ib study of ASC30, an oral GLP-1 receptor agonist, at the European Association for the Study of Diabetes Annual Meeting. The study demonstrated significant weight reduction in participants with obesity and confirmed the drug’s safety and tolerability, with only mild to moderate gastrointestinal side effects. This development highlights Ascletis’ potential to impact the obesity treatment market positively and underscores its commitment to advancing effective therapeutic solutions.
Ascletis Pharma Inc. announced a voluntary lock-up undertaking by its controlling shareholders, Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu, who have committed not to dispose of their shares until the completion of key clinical studies. This move reflects their confidence in the company’s long-term prospects and aims to reassure investors about the company’s future developments in obesity treatment. The lock-up involves 575,952,078 shares, representing approximately 58.03% of the company’s total shares, and is linked to the outcomes of clinical trials expected by the end of 2025.
Ascletis Pharma Inc. has announced the successful demonstration of an ultra-long-acting subcutaneous depot maintenance formulation of its small molecule GLP-1 receptor agonist, ASC30, which showed a 75-day observed half-life in a U.S. Phase Ib study involving participants with obesity. This advancement supports once-quarterly administration, addressing a significant unmet need for maintenance therapy in chronic weight management. The formulation demonstrated favorable tolerability with minimal gastrointestinal side effects, potentially enhancing patient compliance and quality of life.